Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
METARAMINOL MYX (Mayne Pharma International Pty Ltd)
Product name
METARAMINOL MYX
Date registered
Evaluation commenced
Decision date
Approval time
162 working days (255)
Active ingredients
metaraminol tartrate
Registration type
New generic medicine
Indication
METARAMINOL MYX (solution for injection) is indicated for the prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma.
It may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.